{"id":"NCT00620464","sponsor":"Organon and Co","briefTitle":"A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720)","officialTitle":"A Randomized, Double-Blind, Parallel Group, Bioequivalence Study of IMPLANON and Radiopaque IMPLANON","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-05","primaryCompletion":"2009-02","completion":"2009-02","firstPosted":"2008-02-21","resultsPosted":"2010-05-17","lastUpdate":"2022-02-04"},"enrollment":108,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Contraception"],"interventions":[{"type":"DRUG","name":"Radiopaque Implanon","otherNames":[]},{"type":"DRUG","name":"Implanon (etonogestrel implant)","otherNames":[]}],"arms":[{"label":"Radiopaque Implanon (ro imp)","type":"ACTIVE_COMPARATOR"},{"label":"Implanon (imp)","type":"ACTIVE_COMPARATOR"}],"summary":"The primary purpose of this study is to demonstrate the bioequivalence of IMPLANON and Radiopaque IMPLANON.","primaryOutcome":{"measure":"Bioequivalence of ImplanonÂ® and Radiopaque Implanon.","timeFrame":"3 years","effectByArm":[{"arm":"Radiopaque Implanon (ro Imp)","deltaMin":2296,"sd":null},{"arm":"Implanon (Imp)","deltaMin":2290,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.05"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22540269"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":56},"commonTop":["Genital haemorrhage","Vaginal haemorrhage","Implant site haematoma","Nasopharyngitis","Headache"]}}